Strides Pharma Science Singapore arm to acquire 100 percent stake in Amexel

Written by Ruchika Sharma Published On 2025-03-17T17:38:21+05:30 | Updated On 17 March 2025 5:49 PM IST

Strides Pharma Science Singapore arm to acquire 100 percent stake in Amexel

Bangalore: Strides Pharma Global Pte. Limited (SPG), a step-down wholly-owned Subsidiary of Strides Pharma Science Limited in Singapore, has entered into a Share Purchase Agreement to acquire 100 percent stake in Amexel for a nominal consideration of USD 10.

In a recent BSE filing, the Company's Singapore arm proposed to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast Asian countries.

"In this regard, it is proposed to acquire 100% stake in Amexel Pte. Ltd., Singapore (Amexel), which will be utilized as the entity for the above business platform," the Company stated.

Amexel is a company incorporated under the laws of Singapore on March 22, 2023 and has its Registered Office at 36 Robinson Road, #13-06 City House, Singapore 068877.

Amexel is yet to commence its operations.

The acquisition is anticipated to be completed by March 31, 2025.

Amexel, as WOS of SPG, shall focus on in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides’ manufacturing facilities (or those of its affiliates) as well as other manufacturers in India, identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials, building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.

"Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products," the release stated.

strides pharma sciencestrides pharma globalacquisitionamexel

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751